The U.S. Food and Drug Administration (FDA) has approved Infilbray (venglustat) as the first-ever treatment indicated to address the neurological manifestations of Gaucher disease type 3. Developed by Sanofi, the once-daily oral medication was specifically approved for adults and children with type 3 disease who weigh at…
News
Most people with Gaucher disease who were followed at a single center in Turkey received a diagnosis within one year of their first symptoms, but nearly one-quarter experienced a diagnosis delay of at least five years, a small study of 34 people found. About one-third of the participants also…
Delays in diagnosing Gaucher disease remain a challenge, especially in regions where genetic and biomarker testing is limited, according to a recent case report. These delays can postpone treatment and lead to complications that may be difficult or impossible to reverse. The report describes a 60-year-old…
A boy with Gaucher disease went undiagnosed until age 15 despite showing mild symptoms of the disease from infancy, according to a case report from Poland. The researchers said the case highlights how the condition can be difficult to recognize when its early signs are nonspecific. In the boy’s…
This week, on Oct. 1, the International Gaucher Alliance (IGA) is marking International Gaucher Day with the theme “Equity in Action,” highlighting that people with Gaucher disease may be at different stages of their journey and should have access to information, care, and support wherever they are. This…
Skin changes may be more widespread in people with type 1 Gaucher disease (GD1) than previously recognized, with nearly all study participants having at least one, a study shows. The skin manifestations included previously underrecognized changes such as redness of the palms, atypical spots of skin discoloration, and rosacea…
Measuring liver stiffness using a noninvasive imaging technique called magnetic resonance elastography (MRE) may help track disease severity and progression in people with Gaucher disease, a recent study shows. The technique, which combines MRI with low-frequency vibrations to measure organ stiffness, may detect subtle liver changes before more advanced…
Treatment with enzyme replacement therapy (ERT) led to lasting improvements across several laboratory and clinical measures of Gaucher disease in patients from India, despite many starting treatment only after developing advanced disease, a large study found. Most benefits emerged within the first few years of treatment and were…
Among adults receiving treatment for Gaucher disease type 1, greater pain and fatigue were associated with poorer health-related quality of life, according to a study highlighting the need for greater recognition and more targeted care for these persistent symptoms. “These findings support routine integration of validated patient-reported outcome measures…
The first patient has been dosed in a global clinical trial testing the safety and efficacy of FLT201 (avigbagene parvec), an investigational gene therapy that Spur Therapeutics is developing for Gaucher disease type 1. The Phase 3Â trial (NCT07223944) is recruiting up to 45 adults with Gaucher disease…
Recent Posts
- The joy of running has become a metaphor for life with a rare disease
- FDA approves first drug, Infilbray, for neurological problems in Gaucher
- Small study highlights delays in diagnosis in Gaucher disease patients
- Finding my own ‘happily ever after’ in a life with Gaucher disease
- While I was worried about the effects of Gaucher, life happened anyway